Search

Marc A Labroli

from Moorestown, NJ
Age ~54
Get Report
Also known as:
Marc Dr Labroli, Marc Leonardo Robert Labroli, Marc D Labroli, Marc L Labroli, Marc A Labroi, Melissa D Labroli, Marc L, Marc Doyle
Phone and address:
104 W Central Ave, Moorestown, NJ 08057
(619) 638-0894
Related to:
Charmaine R Powell, 88Claudett LabroliJohn LabroliNicholas LabroliDenise Labroli, 64
Connected to:
Maria Labron, 42Martin P Labrosse, 70Toni A Labrozzi, 61Nolan R Labrucherie, 35Dixie L Labrue, 78Amber S Labrum, 53Joseph H Labrum, 82Tiffany D Labrum, 44Kristin N Labruno, 37Nicholas Labruno, 43

Marc Labroli Phones & Addresses

  • 104 W Central Ave, Moorestown, NJ 08057 (619) 638-0894
  • Clifton Heights, PA
  • 36 Overbrook Ave, Longport, NJ 08403 (609) 487-7076
  • Philadelphia, PA
  • 1405 Augusta Cir, Mount Laurel, NJ 08054 (856) 802-9303
  • Glendora, NJ
  • San Diego, CA
  • Atlantic Hl, NJ
  • Burlington, NJ

Work

Company: Merck Oct 1999 Position: Principal scientist

Education

Degree: PostDoc School / High School: The Scripps Research Institute 1997 to 1999 Specialities: Chemistry

Industries

Pharmaceuticals

Resumes

Resumes

Marc Labroli Photo 1

Principal Scientist

View page
Location:
8889 Caminito Plz, San Diego, CA
Industry:
Pharmaceuticals
Work:
Merck since Oct 1999
Principal Scientist
The Scripps Research Institute Jun 1997 - Aug 1999
Postdoctoral
Education:
The Scripps Research Institute 1997 - 1999
PostDoc, Chemistry University of Virginia 1992 - 1997
Ph.D., Chemistry Villanova University 1988 - 1992
B.S., Chemistry Archmere Academy 1984 - 1988

Publications

Us Patents

Piperazine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
6689765, Feb 10, 2004
Filed:
Jan 30, 2002
Appl. No.:
10/061011
Inventors:
Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Elizabeth M. Smith - Verona NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ
Eric Gilbert - Scotch Plains NJ
Marc A. Labroli - Mount Laurel NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31695
US Classification:
514 63, 514 64, 51425212, 51425213, 51425219, 51425301, 5142531, 51425311, 514 2, 514 42, 514 43, 514 45, 514 49, 514220, 514262, 514263
Abstract:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is hydrogen or alkyl; R is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R , R and R are hydrogen or alkyl; R is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

Trisubstituted And Tetrasubstituted Pyrazolopyrimidines As Cyclin Dependent Kinase Inhibitors

View page
US Patent:
7196078, Mar 27, 2007
Filed:
Oct 6, 2005
Appl. No.:
11/245401
Inventors:
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Marc Labroli - Mount Laurel NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Assignee:
Schering Corpoartion - Kenilworth NJ
International Classification:
A61K 31/5513
A61K 31/5355
A61K 31/519
C07D 487/04
C07D 413/04
C07D 417/04
C07D 243/08
A61K 31/541
A61P 19/02
A61P 29/00
C07D 413/06
US Classification:
514218, 540575, 540115, 5142332, 5142285, 5142593, 544281, 544117, 544 61
Abstract:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Piperazine Derivatives Useful As Ccr5 Antagonists

View page
US Patent:
7384944, Jun 10, 2008
Filed:
Sep 23, 2003
Appl. No.:
10/668862
Inventors:
Bahige M. Baroudy - Westfield NJ, US
John W. Clader - Cranford NJ, US
Hubert B. Josien - Jersey City NJ, US
Stuart W. McCombie - Caldwell NJ, US
Brian A. McKittrick - Bloomfield NJ, US
Michael W. Miller - Westfield NJ, US
Bernard R. Neustadt - West Orange NJ, US
Anandan Palani - Kenilworth NJ, US
Elizabeth M. Smith - Verona NJ, US
Ruo Steensma - Weehawken NJ, US
Jayaram R. Tagat - Westfield NJ, US
Susan F. Vice - Mountainside NJ, US
Mark A. Laughlin - Edison NJ, US
Eric Gilbert - Scotch Plains NJ, US
Marc A. Labroli - Mount Laurel NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31/497
US Classification:
51425214, 51425212, 51425213, 51425219, 51425301, 5142531, 51425311
Abstract:
The use of CCR5 antagonists of the formula.

Substituted Pyrazolo[1,5-A]Pyrimidines As Protein Kinase Inhibitors

View page
US Patent:
7605155, Oct 20, 2009
Filed:
Oct 4, 2006
Appl. No.:
11/542920
Inventors:
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Marc Labroli - Mount Laurel NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07D 487/04
C07D 413/06
C07D 417/04
C07D 243/08
A61K 31/519
A61K 31/551
A61K 31/497
A61K 31/541
A61K 31/5355
A61P 35/04
US Classification:
514218, 5142593, 51425216, 5142285, 5142342, 51425505, 544218, 544230, 544117, 544 582, 540575
Abstract:
In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. All illustrative compound is shown below:.

Thiazole Derivatives As Protein Kinase Inhibitors

View page
US Patent:
8476278, Jul 2, 2013
Filed:
Oct 27, 2008
Appl. No.:
12/738487
Inventors:
Panduranga Adulla P. Reddy - Walpole MA, US
Tzu T. Wong - Belmont MA, US
Lianyun Zhao - Burlington MA, US
Shuyi Tang - Belmont MA, US
Marc A. Labroli - Moorestown NJ, US
Timothy J. Guzi - Sudbury MA, US
M. Arshad Siddiqui - Newton MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/496
C07D 417/14
A61K 31/427
A61K 31/551
A61K 31/5377
C07D 413/14
C07D 417/12
C07D 471/10
US Classification:
5142531, 514218, 5142335, 514278, 540575, 544 60, 544 61, 544 62, 544121, 544131, 544133, 544364, 546 16
Abstract:
The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.

Substituted Pyrazolo[1,5-A]Pyrimidines As Cyclin Dependent Kinase Inhibitors

View page
US Patent:
8580782, Nov 12, 2013
Filed:
Apr 20, 2007
Appl. No.:
11/788856
Inventors:
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Marc A. Labroli - Mount Laurel NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/519
A61K 31/5513
A61K 31/5377
A61K 31/541
A61P 35/02
A61P 35/04
A61P 35/00
C07D 487/04
C07D 295/04
C07D 243/14
US Classification:
514218, 544281, 544117, 544 61, 5142593, 5142332, 5142285, 540575
Abstract:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.

Substituted Pyrazolo[1,5-A]Pyrimidines As Cyclin Dependent Kinase Inhibitors

View page
US Patent:
8586576, Nov 19, 2013
Filed:
Feb 23, 2007
Appl. No.:
11/710644
Inventors:
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Marc Labroli - Mount Laurel NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/5513
A61K 31/5377
A61K 31/541
A61K 31/519
A61P 35/04
A61P 35/02
A61P 35/00
C07D 487/04
C07D 295/04
C07D 243/14
US Classification:
514218, 544281, 544117, 544 61, 5142593, 5142332, 5142285, 540575
Abstract:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Modulators Of Cell Cycle Checkpoints And Their Use In Combination With Checkpoint Kinase Inhibitors

View page
US Patent:
8603998, Dec 10, 2013
Filed:
Nov 5, 2008
Appl. No.:
12/744021
Inventors:
Timothy J. Guzi - Sudbury MA, US
David A. Parry - Mountain View CA, US
Marc A. Labroli - Moorestown NJ, US
Michael D. Dwyer - Scotch Plains NJ, US
Kamil Paruch - Tisnov, CZ
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/70
C07H 19/00
A61K 31/535
C07D 487/00
US Classification:
514 49, 536 285, 536 2852, 5142342, 544281
Abstract:
In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.
Control profile
Marc A Labroli from Moorestown, NJ, age ~54 Get Report